The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).

After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

Prominent outside scientists who help the NIH evaluate its internal research programs are being abruptly removed ...

GSK, led by boss Emma Walmsley (pictured), is using the data of 1.4m adults aged 65 and 66 to examine the impact of its ...

GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the ...

Tony Wood, GSK's chief scientific officer ... donanemab are not considered cost-effective for use on the NHS. If the Shingrix jab was confirmed to offer protection, it would mean millions of ...

The research collaboration, which will take four years to complete, will use population-level electronic health data from the NHS to assess the impact of GSK’s recombinant zoster vaccine Shingrix on ...

GSK partners with UK research groups to study if Shingrix shingles vaccine reduces dementia risk, analyzing NHS data from ...

The British drugmaker is using the health data of some 1.4 million people, aged 65 to 66, some of whom received its Shingrix shot and some who did not. Sign up here. GSK's chief scientific officer ...

The recombinant zoster vaccine is effective in preventing herpes zoster in adults aged 50 years or older with rheumatoid ...